Spesolimab

Spesolimab (BI 655130) is a mouse-derived humanized IgG1k antibody against IL-36R. IL-36 plays an important role in the immune system and Spesolimab is being investigated in palmoplantar pustulosis (PPP) . Spesolimab was associated with a reduction in biomarkers associated with the innate, Th1/Th17 and neutrophil pathways[1][2][3][4].

Product Specifications

CAS Number

[2097104-58-8]

Product Name Alternative

BI 655130

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/spesolimab.html

Purity

99.10

Solubility

10 mM in DMSO

Smiles

[Spesolimab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Mrowietz U, et al. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatol Ther (Heidelb) . 2021 Apr;11 (2) :571-585. |[2]Geller S, et al. CCR4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders and its implications for diagnosis and treatment[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2019, 139 (9) : B25-B25. |[3]Jennifer Ahlberg, et al. Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5) . MAbs. 2019 Jul;11 (5) :956-964.|[4]Rajkumar Ganesan, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies.MAbs. 2017 Oct;9 (7) :1143-1154.